Addex Therapeutics Ltd ADXN Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

23:41 EST 3 Dec 2019 | BioPortfolio Reports

Addex Therapeutics Ltd ADXN Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Addex Therapeutics Ltd Addex develops small molecule, orally available, allosteric modulators for neurological disorders. The company's product pipeline consists of its lead products, dipraglurant mGluR5 negative allosteric modulator or NAM to treat Parkinson's disease levodopainduced dyskinesia PDLID and rare forms of dystonia; and ADX71149 mGlu2 positive allosteric modulator or PAM for the treatment of epilepsy. It also conducts clinical and preclinical development of drug candidates for indications such as addiction, CharcotMarieTooth Type 1a CMT1A disease, mild cognitive impairment, psychiatric disorders, Parkinson's disease, and other neurodegenerative disorders. Addex is headquartered in PlanlesOuates, Geneva, Switzerland.

Addex Therapeutics Ltd Key Recent Developments

Jan 07,2019: Addex Trading update: completes 2018 with strong cash position

Sep 28,2018: Addex reports 2018 halfyear financial results and provides corporate update

Apr 30,2018: Addex Announces 2017 Full Year Results

Mar 30,2018: Addex reports 2018 full year audited results and provides corporate update

Mar 20,2018: Swiss Takeover Board Validates New Article 39 OptingOut Provision of Addex Articles of Association

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Addex Therapeutics Ltd ADXN Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110


More From BioPortfolio on "Addex Therapeutics Ltd ADXN Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110"

Quick Search

Relevant Topics

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...